EQUITY (Narrative) (Details) $ / shares in Units, $ / shares in Units, ₪ in Thousands, $ in Thousands |
|
|
|
1 Months Ended |
12 Months Ended |
|
|
|
|
|
Nov. 12, 2024
CAD ($)
shares
|
Nov. 12, 2024
USD ($)
$ / shares
|
May 08, 2023
CAD ($)
shares
|
May 08, 2023
USD ($)
$ / shares
|
Mar. 14, 2022
CAD ($)
$ / shares
shares
|
Mar. 14, 2022
ILS (₪)
|
Oct. 31, 2024
CAD ($)
Shares
$ / shares
shares
|
Feb. 28, 2023
CAD ($)
shares
|
Feb. 28, 2023
USD ($)
$ / shares
shares
|
Aug. 19, 2022
CAD ($)
shares
|
Aug. 19, 2022
USD ($)
shares
|
Mar. 28, 2022
CAD ($)
$ / shares
shares
|
Mar. 28, 2022
ILS (₪)
|
Dec. 31, 2024
CAD ($)
Shares
$ / shares
shares
|
Dec. 31, 2023
CAD ($)
Shares
$ / shares
shares
|
Dec. 31, 2023
USD ($)
Shares
shares
|
Dec. 31, 2022
CAD ($)
Shares
$ / shares
shares
|
Nov. 12, 2024
$ / shares
|
Oct. 31, 2024
$ / shares
|
May 08, 2023
USD ($)
$ / shares
shares
|
Feb. 28, 2023
USD ($)
$ / shares
shares
|
Oct. 31, 2022
CAD ($)
|
Oct. 31, 2022
USD ($)
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
3,085,452
|
2,232,359
|
|
|
|
|
|
|
|
|
Proceeds from issuing shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 944,000
|
$ 1,688,000
|
|
$ 3,756,000
|
|
|
|
|
|
|
Common shares issued as debts settlement with related parties | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
82,082
|
82,082
|
0
|
|
|
|
|
|
|
Gross proceeds from warrants recorded as Share capital and premium |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,154,000
|
$ 7,253,000
|
|
|
|
|
|
|
|
|
Number of warrants exercised | Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,167,000
|
9,167,000
|
0
|
|
|
|
|
|
|
Weighted average value of each option grant | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3
|
$ 6.6
|
|
$ 65.1
|
|
|
|
|
|
|
Number of share options exercised | Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,784
|
|
|
|
|
|
|
Exercise price of compensation option | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 96
|
|
|
|
|
|
|
Number of share options granted | Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
31,305
|
500
|
500
|
5,417
|
|
|
|
|
|
|
Share-based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 369,000
|
$ 225,000
|
|
$ 2,637,000
|
|
|
|
|
|
|
Number of compensation warrants to acquired | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
14
|
|
|
|
|
|
|
|
|
|
Repayments of borrowings, classified as financing activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,834,000
|
4,827,000
|
|
$ 4,976,000
|
|
|
|
|
|
|
Borrowings |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 15,611,000
|
$ 12,513,000
|
|
|
|
|
|
|
|
|
Common Shares issued as a result of options exercises | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
3,622
|
|
|
|
|
|
|
Value of shares issued options exercises |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 333,000
|
|
|
|
|
|
|
Common shares issued upon RSUs vested | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
9,167
|
9,167
|
0
|
|
|
|
|
|
|
L5 Capital [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
82,082
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
82,082
|
|
|
|
Par value per share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 7
|
|
|
|
Exercise price of warrants issued per common share | $ / shares |
|
|
|
$ 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
36 months
|
36 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayments of borrowings, classified as financing activities |
|
|
$ 839,000
|
$ 616
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Private Placements [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
|
|
|
|
|
|
100,000
|
100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuing shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,756,000
|
$ 3,000
|
|
|
|
|
|
|
|
Transaction costs incurred for common share issuance |
|
|
|
|
|
|
|
|
|
$ 178,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds from issuance of units |
|
|
|
|
|
|
|
|
|
$ 6,500,000
|
$ 5,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharm Yarok [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
|
8,728
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Par value per share | $ / shares |
|
|
|
|
$ 156.96
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuing shares |
|
|
|
|
$ 1,370,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vironna pharmacy [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
|
8,089
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Par value per share | $ / shares |
|
|
|
|
$ 134.88
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuing shares |
|
|
|
|
$ 1,091,000
|
₪ 3,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oranim Pharm [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
|
|
|
|
|
|
|
|
4,184
|
|
|
|
|
|
|
|
|
|
|
|
Par value per share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
$ 150.6
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuing shares |
|
|
|
|
|
|
|
|
|
|
|
$ 600,000
|
₪ 1,500
|
|
|
|
|
|
|
|
|
|
|
Life Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
|
|
|
|
471,375
|
|
|
|
|
|
|
|
|
|
|
|
|
471,375
|
|
|
Par value per share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 7.5
|
|
|
Proceeds from issuing shares |
|
|
|
|
|
|
|
$ 4,705,000
|
$ 3,535
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants issued per common share | $ / shares |
|
|
|
|
|
|
|
|
$ 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
36 months
|
36 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct and incremental transaction costs |
|
|
|
|
|
|
|
$ 334,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Concurrent Offering [Member] | Non-brokered private placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
|
|
|
|
386,195
|
|
|
|
|
|
|
|
|
|
|
|
|
386,195
|
|
|
Par value per share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 7.5
|
|
|
Proceeds from issuing shares |
|
|
|
|
|
|
|
$ 3,854,000
|
$ 2,896
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants issued per common share | $ / shares |
|
|
|
|
|
|
|
|
$ 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
36 months
|
36 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total concurrent offering units | shares |
|
|
|
|
|
|
|
193,333
|
193,333
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January February 2023 Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative liability |
|
|
|
|
|
|
|
$ 7,027,000
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,277
|
|
|
Transaction costs incurred for common share issuance |
|
|
|
|
|
|
|
268,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January February 2023 Warrants [Member] | Share Capital [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds from warrants recorded as Share capital and premium |
|
|
|
|
|
|
|
1,754,000
|
$ 1,319
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Transaction costs incurred for common share issuance |
|
|
|
|
|
|
|
$ 66,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
May 2023 Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative liability |
|
|
226,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 166
|
|
|
|
May 2023 Warrants [Member] | Share Capital [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds from warrants recorded as Share capital and premium |
|
|
$ 613,000
|
$ 450
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
November 2024 Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Transaction costs incurred for common share issuance |
$ 1,154,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct and incremental transaction costs |
49,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recorded as deduction from share capital and premium |
$ 40,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
November 2024 Warrants [Member] | Non-brokered private placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
742,517
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Par value per share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.88
|
|
|
|
|
|
Proceeds from issuing shares |
|
$ 2,138
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants issued per common share | $ / shares |
|
$ 4.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct and incremental transaction costs |
$ 89,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
November 2024 Warrants [Member] | Share Capital [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Transaction costs incurred for common share issuance |
$ 984,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre Funded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 496,000
|
|
|
|
|
|
|
|
|
|
(Gain) loss on revaluation |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 56,000
|
|
|
|
|
|
|
|
|
|
Various Institutions [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Borrowings |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,832,000
|
$ 8,000
|
Non-Independent Director [Member] | Life Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants issued per common share | $ / shares |
|
|
|
|
|
|
|
|
$ 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
36 months
|
36 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number Of Shared Subscribed | shares |
|
|
|
|
|
|
|
21,950
|
21,950
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value Of Shared Subscribed |
|
|
|
|
|
|
|
$ 222,000
|
$ 165
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Guarantor (Chairman & CEO) [Member] | Pre Funded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Par value per share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2.88
|
|
|
|
|
Common shares issued as debts settlement with related parties | shares |
|
|
|
|
|
|
110,576
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of warrants issued for common shares | Shares |
|
|
|
|
|
|
152,701,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants issued per common share | $ / shares |
|
|
|
|
|
|
$ 0.00001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative liability |
|
|
|
|
|
|
$ 440,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of common shares recognized as part of permanent equity |
|
|
|
|
|
|
$ 318,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Guarantor (Chairman & CEO) [Member] | Various Institutions [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Personal Guarantee Value (Benefit) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 758,000
|
$ 560
|
2018 Share Incentive Plan" (the "2018 Plan") [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares available for future grants | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,310,142
|
|
|
|
|
|
|
|
|
|
Weighted average fair value of each option grant |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.24
|
$ 4.7
|
|
$ 5.32
|
|
|
|
|
|
|
Weighted average remaining contractual life for the share options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
1 year 9 months 10 days
|
3 years 9 months 3 days
|
3 years 9 months 3 days
|
|
|
|
|
|
|
|
2018 Share Incentive Plan" (the "2018 Plan") [Member] | Vest on the first anniversary of the applicable vesting commencement date [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards vest |
|
|
|
|
|
|
|
|
|
|
|
|
|
33.30%
|
|
|
|
|
|
|
|
|
|
2018 Share Incentive Plan" (the "2018 Plan") [Member] | Vest in eight equal installments upon the lapse of each three-month period thereafter [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Disclosure of terms and conditions of share-based payment arrangement [line items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards vest |
|
|
|
|
|
|
|
|
|
|
|
|
|
66.70%
|
|
|
|
|
|
|
|
|
|